Loperamide 1980s, prior to the expiration of US patent on 30 January 1990, McNeil company started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas. In March 1997, the company patented such combination. The drug was approved in June 1997 by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet. In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology. Imodium Instant Melts from Johnson & Johnson is currently the only loperamide available in the form of orally disintegrating tablets. In 2013, loperamide in the form of
Loperamide with loperamide should be discontinued. The use of loperamide in children under 2 years is not recommended. Rare reports of fatal paralytic ileus associated with abdominal distention have been made. Most of these reports occurred in the setting of acute dysentery, overdose, and with very young children less than 2 years of age. A review of loperamide in children under 12 years old found that serious adverse events occurred only in children under 3 years old. The study reported that the use of loperamide should be contraindicated in children who are under 3, systemically ill, malnourished, moderately dehydrated, or have